Evidence map›Paper›PMID 41918168›Full record

ArticleHGG advances2026

Loss-of-function variants in MARK2 cause neurodevelopmental disorder.

Yunseon Yang, Yoon-Kyung Shim, Noriko Miyake, Sanami Takada, Sebastian Silva, Alexander Peters-Foitzick, Abha R Gupta, Emily Neuhaus, Catherine Bradley, Cora Taylor and 8 more

Abstract read
In one paragraph

Article in HGG advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yunseon YangDepartment of Neurology, Houston Methodist Research Institute, Houston, TX, USA; Department of Neurology, Weill Cornell Medical College, New York, NY, USA.
Yoon-Kyung ShimDepartment of Neurology, Houston Methodist Research Institute, Houston, TX, USA; Department of Neurology, Weill Cornell Medical College, New York, NY, USA.
Noriko MiyakeDepartment of Human Genetics, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Sanami TakadaDepartment of Human Genetics, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Sebastian SilvaChild Neurology Service, Hospital de Puerto Montt, Puerto Montt, Chile; Escuela de Medicina, Universidad San Sebastián, Sede Patagonia, Puerto Montt, Chile.
Alexander Peters-FoitzickChild Neurology Service, Hospital de Puerto Montt, Puerto Montt, Chile; Escuela de Medicina, Universidad San Sebastián, Sede Patagonia, Puerto Montt, Chile.
Abha R GuptaDepartments of Pediatrics, Child Study Center, and Neuroscience, Yale School of Medicine, New Haven, CT, USA.
Emily NeuhausDepartment of Psychiatry & Behavioral Sciences, University of Washington, Seattle, WA, USA; Seattle Children's, Seattle, WA, USA.
Catherine BradleyDepartment of Pediatrics, Medical University of South Carolina, Charleston, SC, USA.
Cora TaylorAutism & Developmental Medicine Institute, Geisinger, Lewisburg, PA, USA.
Bianca RussellDepartment of Human Genetics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, USA.
Amanda ShrewsburyDepartment of Human Genetics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, USA.
Jacob J MichaelsonDepartment of Psychiatry, University of Iowa, Iowa City, IA, USA.
Chaya N MuraliDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA; Texas Children's Hospital, Houston, TX, USA.
Amanda GerardDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA; Texas Children's Hospital, Houston, TX, USA.
Alexa GeltzeilerDepartment of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
Wendy K ChungDepartment of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: wendy.chung@childrens.harvard.edu.
Hyung-Lok ChungDepartment of Neurology, Houston Methodist Research Institute, Houston, TX, USA; Department of Neurology, Weill Cornell Medical College, New York, NY, USA. Electronic address: hchung2@houstonmethodist.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microtubule-affinity regulating kinase 2 (MARK2) is a conserved serine/threonine kinase that plays a critical role in microtubule dynamics and neuronal polarity. Rare MARK2 variants have recently been reported in individuals with autism spectrum disorder (ASD) and neurodevelopmental disorder (NDD), and here we expand the number of affected individuals, including a familial case. Despite these clinical findings, the functional significance and underlying mechanisms of patient-derived variants remain poorly understood. To address this gap, we established a humanized Drosophila model and systematically evaluated eight NDD-linked MARK2 variants using tissue-specific expression assays. Functional assessments in Drosophila indicate that MARK2 variants span a range of functional consequences, primarily exhibiting hypomorphic or loss-of-function effects. Truncating variants consistently showed reduced protein levels and rescued lethality, a loss-of-function mechanism. Most missense variants (e.g., p.Val231Met, p.Gly135Arg, p.Ala80Val, and p.His167Pro) maintained protein expression and induced mild to moderate phenotypes, consistent with partial loss of function. The p.Lys224Glu variant behaved similarly to the wild type in both viability and wing patterning assays and exhibited elevated protein levels but did not display overt pathogenicity in flies. Based on these findings, we propose a functional classification of MARK2 variants into three categories: not pathogenic (p.Lys224Glu), hypomorphic (missense variants), and loss of function (truncating variants). These results highlight the value of Drosophila as a scalable in vivo platform for variant interpretation and provide insight into how reduced MARK2 activity may contribute to neurodevelopmental disorders.

Indexed as

Loss of Function MutationNeurodevelopmental DisordersProtein Serine-Threonine KinasesAnimalsDisease Models, AnimalDrosophilaGenetic Predisposition to DiseaseHumansPhenotypeMARK2 protein, humanProtein Serine-Threonine Kinasesautism spectrum disorderdrosophila modelgenotype-phenotype correlationhypomorphic variantsMARK2neurodevelopmental disordervariant functional classificationvariant of uncertain significance

Identifiers

PMID41918168
PMCPMC13127627

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.